| Literature DB >> 16860394 |
Yasumasa Ohyagi1, Yuko Tsuruta, Kyoko Motomura, Katsue Miyoshi, Hitoshi Kikuchi, Toru Iwaki, Takayuki Taniwaki, Jun-ichi Kira.
Abstract
Amyloid beta-protein ending at 42 (Abeta42) is the major peptide deposited in Alzheimer's disease (AD) brain. In immunocytochemical studies, formic acid treatment is used to dramatically enhance Abeta immunoreactivity. Recently, Abeta42 has been reported to accumulate in AD neurons. Since heating is known to enhance intracellular protein immunoreactivity, we used an autoclaving protocol to enhance intraneuronal Abeta42 immunoreactivity. Using this protocol, both anti-Abeta42 N-terminal and C-terminal antibodies, but not anti-Abeta40 C-terminal antibody, labeled AD neurons. Moreover, formic acid treatment counteracted such effects of autoclaving. Thus, intraneuronal Abeta42 accumulation may have been underestimated by conventional methods using formic acid only.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16860394 DOI: 10.1016/j.jneumeth.2006.06.010
Source DB: PubMed Journal: J Neurosci Methods ISSN: 0165-0270 Impact factor: 2.390